专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2014018883A1 CATALYTIC CONVERTER, A KIT FOR SERVICING A CATALYTIC CONVERTER, AND METHOD FOR SERVICING A CATALYTIC CONVERTER 审中-公开
标题翻译：催化转化器，用于维修催化转化器的工具包和用于维修催化转化器的方法
公开(公告)号：WO2014018883A1
公开(公告)日：2014-01-30
申请号：PCT/US2013/052321
申请日：2013-07-26
申请人： SERVAAS LABORATORIES, INC.
发明人： SERVAAS, Paul , MILLER, Ryan, Scott
IPC分类号： F01N3/24 , F01N3/28 , B01D53/94 , B60S5/00
CPC分类号： F01N3/28 , B01D53/94 , B01D53/96 , F01N3/10 , F01N3/206 , F01N13/18 , F01N2260/04 , F01N2450/00 , Y02T10/24 , Y10T29/49345 , Y10T29/49826
摘要： A method is disclosed. The method comprises the steps of preparing a serviceable catalytic converter (108) such that a catalyst substrate (144) of the catalytic converter (108) is serviceable while the catalytic converter (108) remains connected to an exhaust system (100) by forming a lower surface (108b) of the body (124) of the catalytic converter (108) with an absence of material in order to provide at least one opening (148, 148a, 148b) in the lower surface (108b) of the body (124) of the catalytic converter (108) for permitting selective access to a fluid- flow passage (136) that extends through the body (124) of the catalytic converter (108) that contains the catalyst substrate (144); and disposing at least one close-out member (175, 175a, 175b) in the at least one opening (148, 148a, 148b) for fluidly-sealing the at least one opening (148, 148a, 148b). A component (108) of an exhaust system (100) that is serviceable while remaining fluidly-connected and physically-connected to the exhaust system (100) is also disclosed. A kit (K) for servicing a component (108) of an exhaust system (100) that is serviceable while remaining fluidly-connected and physically-connected to the exhaust system (100) is also disclosed.
摘要翻译：公开了一种方法。该方法包括以下步骤：制备可使用的催化转化器（108），使得催化转化器（108）的催化剂基底（144）可使用，同时催化转化器（108）保持与排气系统（100）连接，形成催化转化器（108）的主体（124）的下表面（108b）没有材料，以便在主体（124）的下表面（108b）中提供至少一个开口（148,148a，148b）），用于允许选择性地进入延伸穿过包含催化剂衬底（144）的催化转化器（108）的主体（124）的流体流动通道（136）; 以及在所述至少一个开口（148,148a，148b）中设置至少一个闭合构件（175,175a，175b），用于流体地密封所述至少一个开口（148,148a，148b）。还公开了一种能够在保持流体连接并物理连接到排气系统（100）的同时可使用的排气系统（100）的部件（108）。还公开了一种用于维修排气系统（100）的组件（108）的工具（K），其可以在保持流体连接并物理连接到排气系统（100）的同时可使用。

2. 发明申请

WO2013185112A1 PHARMACEUTICL COMPOSITIONS FOR THE TREATMENT OF CFTR -MEDIATED DISORDERS 审中-公开
标题翻译：用于治疗CFTR相关疾病的药物组合物
公开(公告)号：WO2013185112A1
公开(公告)日：2013-12-12
申请号：PCT/US2013/044838
申请日：2013-06-07
申请人： VERTEX PHARMACEUTICALS INCORPORATED
发明人： VAN GOOR, Fredrick, F.
IPC分类号： A61K31/404 , A61K31/44 , A61K31/47 , A61P43/00
CPC分类号： C07D215/56 , A61K9/08 , A61K9/1617 , A61K9/1652 , A61K9/2018 , A61K9/2054 , A61K9/2077 , A61K9/4858 , A61K9/4866 , A61K31/404 , A61K31/443 , A61K31/47 , A61K45/06 , A61K47/10 , A61K47/26 , A61K47/32 , A61K47/38 , C07D405/12 , A61K2300/00
摘要： The present invention relates to the use of N-[2,4-bis(1,1-dimethylethyl)-5- hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxaraide (Compound 1), solids forms, and pharmaceutical compositions thereof for the treatment of CFTR-mediated diseases, particularly cystic fibrosis, in patients possessing specific genetic mutations. The present invention also relates to the use of Compound ί in combination with 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxoI- 5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 2), and Compound 1 in combination with (S)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3- dihydroxypropyl)~6~fluoro-2-( 1 -hydroxy-2-methylpropan-2-yl)- 1H-indol-5- yl)cyclopropanecarboxamide (Compound 3), for the treatment of CFTR-mediated diseases, particularly cystic fibrosis, in patients possessing specific genetic mutations. The present invention also relates to solid forms and formulations of Compound 2 or Compound 3 in combination with Compound 1, and pharmaceutical compositions thereof, for the treatment of CFTR-mediated diseases, particularly cystic fibrosis, in patients possessing specific genetic mutations.
摘要翻译：本发明涉及使用N- [2,4-双（1,1-二甲基乙基）-5-羟基苯基] -1,4-二氢-4-氧代喹啉-3-甲酰胺（化合物1），固体形式，及其药物组合物，用于治疗具有特定遗传突变的患者中CFTR介导的疾病，特别是囊性纤维化。本发明还涉及化合物I与3-（6-（1-（2,2-二氟苯并[d] [1,3]二氧代-5-基）环丙烷甲酰氨基）-3-甲基吡啶-2 - 基）苯甲酸（化合物2）和化合物1与（S）-1-（2,2-二氟苯并[d] [1,3]二氧杂环戊烯-5-基）-N-（1-（2 ，3-二羟丙基）-6-氟-2-（1-羟基-2-甲基丙-2-基）-1H-吲哚-5-基）环丙烷甲酰胺（化合物3），用于治疗CFTR介导的疾病，特别是囊性纤维化，具有特异性遗传突变的患者。本发明还涉及化合物2或化合物3与化合物1组合的固体形式和制剂及其药物组合物，用于治疗具有特定遗传突变的患者的CFTR介导的疾病，特别是囊性纤维化。

3. 发明申请

WO2013163530A2 ELECTRON IMPACT ION SOURCE WITH FAST RESPONSE 审中-公开
标题翻译：电子影响离子源与快速反应
公开(公告)号：WO2013163530A2
公开(公告)日：2013-10-31
申请号：PCT/US2013/038388
申请日：2013-04-26
申请人： LECO CORPORATION
发明人： VERENCHIKOV, Anatoly, N.
IPC分类号： H01J49/14
CPC分类号： H01J49/147 , G01N30/7206 , H01J49/0468 , H01J49/40
摘要： A closed electron impact ion source with overall opening area of less than 30mm 2 is employed for direct and pulsed extraction into a time-flight mass spectrometer in order to enhance sensitivity and immunity to chemical noise of oil and fumes of the vacuum system. For compatibility with dual stage GCxGC separation, the source may contain an inert liner surrounded by an isothermal cage of thermally conductive material. The source inner surface may be reduced to under 100mm 2 . A portion of carrier gas may be pumped down before admitting the sample and carrier gas into the source. A cooled surface may be used to condense fumes at the analysis time.
摘要翻译：整个开口面积小于30mm2的封闭电子冲击离子源用于直接和脉冲提取到时间飞行质谱仪中，以提高真空系统的油和烟雾的化学噪声的灵敏度和抗扰性。为了与双级GCxGC分离兼容，源可以包含被导热材料的恒温笼包围的惰性衬垫。源内表面可以减少到100mm2以下。在将样品和载气进入源之前，可以将一部分载气抽出。冷却的表面可用于在分析时间浓缩烟雾。

4. 发明申请

WO2013142124A8 SOLID FORMS OF A THIOPHOSPHORAMIDATE NUCLEOTIDE PRODRUG 审中-公开
公开(公告)号：WO2013142124A8
公开(公告)日：2013-09-26
申请号：PCT/US2013/030267
申请日：2013-03-11
申请人： VERTEX PHARMACEUTICALS INCORPORATED
发明人： KULDIPKUMAR, Anuj, K. , MEDEK, Ales , FERRIS, Lori, Ann , MUDUNURI, Praveen , JUNG, Young, Chun , WILLCOX, David, Richard , WALDO, Michael , NUGENT, William, Aloysius
IPC分类号： C07H19/06 , A61K31/7072 , A61P31/14
摘要： The present application relates to solid state forms, for example, crystalline forms of 2'-C-methyluridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, pharmaceutical compositions that can include one or more solid forms of 2'-C-methyluridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, and methods of treating or ameliorating diseases and/or conditions with one or more solid forms of 2'-C-methyluridine-5'-(O-phenyl-N-(S)-1-(isopropoxy carbonyl)ethyl)thiophosphoramidate. Also disclosed herein are methods of treating diseases and/or conditions with one or more solid forms of 2'-C-methyluridine-5'-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate in combination with one or more other agents.

5. 发明申请

WO2012044574A1 DUAL INHIBITORS OF MET AND VEGF FOR THE TREATMENT OF CASTRATION RESISTANT PROSTATE CANCER AND OSTEOBLASTIC BONE METASTASES 审中-公开
标题翻译： MET和VEGF用于治疗耐药前列腺癌和骨质疏松性骨质疏松症的双重抑制剂
公开(公告)号：WO2012044574A1
公开(公告)日：2012-04-05
申请号：PCT/US2011/053240
申请日：2011-09-26
申请人： EXELIXIS, INC. , SMITH, David , HUSSAIN, Maha
发明人： SMITH, David , HUSSAIN, Maha
IPC分类号： A61K31/00 , A61K31/5377 , A61K31/47 , A61P35/00 , A61P35/04
CPC分类号： A61K31/5377 , A61K31/00 , A61K31/47
摘要： This invention is directed to the treatment of cancer, particularly castration- resistant prostate cancer and osteoblastic bone metastases, with a dual inhibitor of MET and VEGF.
摘要翻译：本发明涉及用MET和VEGF的双重抑制剂治疗癌症，特别是去势抗性前列腺癌和成骨细胞骨转移瘤。

6. 发明申请

WO2012037204A1 INHIBITORS OF PI3K-DELTA AND METHODS OF THEIR USE AND MANUFACTURE 审中-公开
标题翻译： PI3K-DELTA抑制剂及其使用和制造方法
公开(公告)号：WO2012037204A1
公开(公告)日：2012-03-22
申请号：PCT/US2011/051531
申请日：2011-09-14
申请人： EXELIXIS, INC. , LEAHY, James, William
发明人： LEAHY, James, William
IPC分类号： C07D215/06 , C07D241/44 , C07D401/14 , C07D405/12 , C07D413/14 , C07D473/34 , C07D495/04 , A61P35/00 , A61K31/52 , A61K31/4709 , A61K31/47 , A61K31/497 , A61K31/551 , A61K31/5377
CPC分类号： C07D473/38 , C07D213/30 , C07D213/38 , C07D215/12 , C07D215/14 , C07D215/38 , C07D241/44 , C07D295/125 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D413/14 , C07D417/14 , C07D473/34 , C07D487/04 , C07D495/04 , C07D519/00
摘要： The invention is directed to Compounds of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.
摘要翻译：本发明涉及式I化合物：及其药学上可接受的盐或溶剂合物，以及制备和使用该化合物的方法。

7. 发明申请

WO2012009503A1 PALATABLE PHARMACEUTICAL COMPOSITION COMPRISING VX-950 审中-公开
标题翻译：包含VX-950的可食用药物组合物
公开(公告)号：WO2012009503A1
公开(公告)日：2012-01-19
申请号：PCT/US2011/043950
申请日：2011-07-14
申请人： DOKOU, Eleni , VERTEX PHARMACEUTICALS INCORPORATED
发明人： DOKOU, Eleni
IPC分类号： A61K31/497 , A61K9/20 , A61P31/12 , A61K38/07 , A61K38/55
CPC分类号： A61K31/497 , A61K9/0056 , A61K9/145 , A61K9/2054 , A61K9/2077
摘要： A pharmaceutical formulation comprising: VX-950; and a taste improving composition.
摘要翻译：一种药物制剂，其包含：VX-950; 和味道改善组合物。

8. 发明申请

WO2011156545A1 VIRAL DYNAMIC MODEL FOR HCV COMBINATION THERAPY 审中-公开
标题翻译： HCV组合治疗的病毒动态模型
公开(公告)号：WO2011156545A1
公开(公告)日：2011-12-15
申请号：PCT/US2011/039712
申请日：2011-06-09
申请人： VERTEX PHARMACEUTICALS INCORPORATED , ADIWIJAYA, Bambang, Senoaji , CARON, Paul, R. , GARG, Varun , KIEFFER, Tara, Lynn , KWONG, Ann Dak-Yee , KAUFFMAN, Robert, S.
发明人： ADIWIJAYA, Bambang, Senoaji , CARON, Paul, R. , GARG, Varun , KIEFFER, Tara, Lynn , KWONG, Ann Dak-Yee , KAUFFMAN, Robert, S.
IPC分类号： G01N33/576 , G06F19/00
CPC分类号： G01N33/5767
摘要： A model of HCV dynamics to quantify responses in subjects dosed with a combination of PR and a protease inhibitor is provided. The model quantitatively predicts clinical outcomes of alternative durations of the protease inhibitor and PR, and these predictions correspond well to the empirically observed outcomes in clinical trials. This model accounts for multiple HCV variants with reduced replicative fitness and susceptibility to protease inhibitors, and examines how these properties of the variants contribute to the HCV dynamics in subjects dosed with the triple combination therapy. Furthermore, the model provides insight into the mechanisms of how protease inhibitor-based regimens increase the SVR rate and reduce total duration of treatment, and predicts that the protease inhibitor-mediated reduction in the overall fitness of the HCV quasispecies, along with potential synergy of protease inhibitors and PR, may enable previous PR nonresponders to achieve SVR on T/PR treatment.
摘要翻译：提供了HCV动力学模型，用于定量给予PR和蛋白酶抑制剂组合的受试者的反应。该模型定量预测了蛋白酶抑制剂和PR的替代持续时间的临床结果，这些预测与临床试验中经验观察到的结果很好地吻合。该模型考虑了多种HCV变异体，其具有降低的复制适应性和对蛋白酶抑制剂的易感性，并且检查这些变体的这些性质如何有助于用三联组合治疗的受试者的HCV动态。此外，该模型提供了对蛋白酶抑制剂方案如何增加SVR率和减少治疗总持续时间的机制的了解，并预测蛋白酶抑制剂介导的HCV准种总体适应性的降低以及潜在的协同作用蛋白酶抑制剂和PR，可以使先前的PR无应答者在T / PR治疗上实现SVR。

9. 发明申请

WO2011143362A1 DIMERIC OXIDATION-RESISTANT APOLIPOPROTEIN A1 VARIANTS 审中-公开
标题翻译：二氧化硫抗氧化蛋白A1变体
公开(公告)号：WO2011143362A1
公开(公告)日：2011-11-17
申请号：PCT/US2011/036144
申请日：2011-05-11
申请人： ESPERION THERAPEUTICS, INC. , NEWTON, Roger, S. , SRIVASTAVA, Ajit, K. , HURLEY, Tim , CRAMER, Clay , FILIPPOV, Sergey, V. , PINKOSKY, Stephen, L.
发明人： NEWTON, Roger, S. , SRIVASTAVA, Ajit, K. , HURLEY, Tim , CRAMER, Clay , FILIPPOV, Sergey, V. , PINKOSKY, Stephen, L.
IPC分类号： A61K38/17 , C07K14/775
CPC分类号： C07K14/775 , A61K38/00
摘要： An isolated oxidation-resistant ApoA1 variant dimer includes a first oxidation-resistant ApoA1 variant polypeptide monomer and a second oxidation-resistant ApoA1 variant polypeptide monomer, wherein at least one of the first and the second monomers comprises at least one amino acid substitution of a tryptophan residue for an oxidation resistant amino acid, or a functional fragment or variant thereof. Methods for treating a disease or disorder comprises administering to a subject in need thereof, a therapeutically effective amount of an isolated oxidation-resistant ApoA1 variant dimer, an oxidation-resistant ApoA1 variant monomer, an oxidation-resistant ApoA1 monomer -lipid complex, a lipid complexed oxidation-resistant ApoA1 variant monomer, a lipid complexed oxidation-resistant ApoA1 variant dimer, or combinations thereof to the subject to enhance cholesterol efflux activity in the presence of an oxidant.
摘要翻译：分离的抗氧化ApoA1变体二聚体包括第一抗氧化ApoA1变体多肽单体和第二抗氧化ApoA1变体多肽单体，其中第一和第二单体中的至少一个包含至少一个色氨酸的氨基酸取代用于抗氧化氨基酸的残基或其功能片段或变体。用于治疗疾病或病症的方法包括向有需要的受试者施用治疗有效量的分离的抗氧化ApoA1变体二聚体，抗氧化ApoA1变体单体，抗氧化ApoA1单体脂质复合物，脂质复合抗氧化ApoA1变体单体，脂质复合抗氧化ApoA1变体二聚体或其组合，以增强氧化剂存在下的胆固醇流出活性。

10. 发明申请

WO2011133953A1 PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF 审中-公开
标题翻译：药物组合物及其药理学
公开(公告)号：WO2011133953A1
公开(公告)日：2011-10-27
申请号：PCT/US2011/033689
申请日：2011-04-22
申请人： VERTEX PHARMACEUTICALS INCORPORATED , VAN GOOR, Fredrick, F. , ALARGOVA, Rossitza, Gueorguieva , ALCACIO, Tim, Edward , AREKAR, Sneha, G. , BINCH, Hayley, Marie , BOTFIELD, Martyn, Curtis , FANNING, Lev, Tyler Dewey , GROOTENHUIS, Peter, Diederik Jan , HURLEY, Dennis, James , JOHNSTON, Steven, C. , KADIYALA, Irina, Nikolaevna , KAUSHIK, Ritu, Rohit , KESHAVARZ-SHOKRI, Ali , KRAWIEC, Mariusz , LEE, Elaine, Chungmin , LUISI, Brian , MEDEK, Ales , MUDUNURI, Praveen , NUMA, Mehdi , SHETH, Urvi Jagdishbhai , SILINA, Alina , SULLIVAN, Mark Jeffrey , VERWIJS, Marinus Jacobus , YANG, Xiaoqing , YOUNG, Christopher Ryan , ZAMAN, Noreen Tasneem , ZHANG, Beili , ZHANG, Yuegang , ZLOKARNIK, Gregor
发明人： VAN GOOR, Fredrick, F. , ALARGOVA, Rossitza, Gueorguieva , ALCACIO, Tim, Edward , AREKAR, Sneha, G. , BINCH, Hayley, Marie , BOTFIELD, Martyn, Curtis , FANNING, Lev, Tyler Dewey , GROOTENHUIS, Peter, Diederik Jan , HURLEY, Dennis, James , JOHNSTON, Steven, C. , KADIYALA, Irina, Nikolaevna , KAUSHIK, Ritu, Rohit , KESHAVARZ-SHOKRI, Ali , KRAWIEC, Mariusz , LEE, Elaine, Chungmin , LUISI, Brian , MEDEK, Ales , MUDUNURI, Praveen , NUMA, Mehdi , SHETH, Urvi Jagdishbhai , SILINA, Alina , SULLIVAN, Mark Jeffrey , VERWIJS, Marinus Jacobus , YANG, Xiaoqing , YOUNG, Christopher Ryan , ZAMAN, Noreen Tasneem , ZHANG, Beili , ZHANG, Yuegang , ZLOKARNIK, Gregor
IPC分类号： A61K31/4704 , A61K31/404 , A61K31/443
CPC分类号： A61K31/4709 , A61K31/404 , A61K31/443 , A61K31/4433 , A61K31/47 , A61K31/4704 , G01N33/6872 , G01N2333/4703 , A61K2300/00
摘要： The present invention relates to pharmaceutical compositions comprising a compound of Formulas I and II, optionally in combination with a Compound of Formula III and/or a Compound of Formula IV. The invention also relates to solid forms and to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis.
摘要翻译：本发明涉及包含式I和II化合物，任选与式III化合物和/或式IV化合物组合的药物组合物。本发明还涉及固体形式及其药物制剂，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式